The potential of individualized dosing of ravulizumab to improve patient‐friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costs

Ravulizumab is a very expensive complement C5‐inhibitor for the treatment of paroxysmal nocturnal haemoglobinuria, with a fixed‐dosing interval of 8 weeks. For lifelong treatment, a cost‐effective and patient‐friendly dosing strategy is preferred. We therefore explored alternative ravulizumab dosing...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	British journal of clinical pharmacology 2021-08, Vol.87 (8), p.3359-3363
Hauptverfasser:	Avest, Mendy, Langemeijer, Saskia M.C., Schols, Saskia E.M., Burger, David M., Kar, Nicole C.A.J., Blijlevens, Nicole M.A., Kievit, Wietske, Heine, Rob
Format:	Artikel
Sprache:	eng
Schlagworte:	paroxysmal nocturnal haemoglobinuria pharmacodynamics pharmacokinetics ravulizumab Short Report Short Reports
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!